Biosimilars in an era of rising oncology treatment options - Archive ouverte HAL Access content directly
Journal Articles Future Oncology Year : 2021

Biosimilars in an era of rising oncology treatment options

(1) , (2, 3) , (4) , (5) , (6, 7) , (8)
1
2
3
4
5
6
7
8

Abstract

New diagnostic technologies, including molecular profiling, have enabled advances in treatments of various cancers; this has significantly improved clinical outcomes, including overall survival. However, the high cost of biologic drugs may prevent patients from having access to optimal treatment. Introduction of lower priced biosimilar agents into the therapeutic armamentarium brings the potential to ease the burden on healthcare expenditure and facilitate better access to effective cancer treatments. Oncology biosimilars have shown comparable efficacy and safety based on clinical evidence and physicochemical quality data as well as in real-world settings. This paper aims to review changes in the management of oncology treatment and their implication with respect to biosimilars.
Fichier principal
Vignette du fichier
fon-2021-0546.pdf (1.41 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

hal-03635306 , version 1 (31-10-2022)

Identifiers

Cite

Marc Peeters, David Planchard, Mark Pegram, João Gonçalves, François Bocquet, et al.. Biosimilars in an era of rising oncology treatment options. Future Oncology, 2021, 17 (29), pp.3881-3892. ⟨10.2217/fon-2021-0546⟩. ⟨hal-03635306⟩
8 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More